Alseres Raises $5 Million From Former Director, Robert Gipson
Luke Timmerman6/30/08
Alseres Pharmaceuticals, (NASDAQ: ALSE) a developer of neurological drugs and diagnostics, said today it raised $5 million in convertible debt from Robert Gipson, a General Partner of Ingalls & Snyder Value Partners, and a former director of the company. Gipson can convert the loan principal into shares of the company’s stock at $2.50 a share. The Hopkinton, MA-based company’s shares climbed 4 cents to $2.34 at 1:34 p.m. Eastern time today, following the announcement.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
